Emerging evidence from recent studies suggests that CBX proteins are associated with a variety of tumors. CBX2 inhibition induces cancer cell death, positioning CBX2 as an attractive drug target for the treatment of advanced prostate cancer [8]. Here, CBX2 is linked to prostate carcinoma.